Elizabeth Henry

ORCID: 0000-0003-2948-3985
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Bladder and Urothelial Cancer Treatments
  • Social Media in Health Education
  • Urinary and Genital Oncology Studies
  • Cancer Immunotherapy and Biomarkers
  • Prostate Cancer Treatment and Research
  • COVID-19 and healthcare impacts
  • Advances in Oncology and Radiotherapy
  • Cancer Diagnosis and Treatment
  • Prostate Cancer Diagnosis and Treatment
  • Health Literacy and Information Accessibility
  • Radiology practices and education
  • Web and Library Services
  • Patient-Provider Communication in Healthcare
  • Diversity and Career in Medicine
  • Multiple and Secondary Primary Cancers
  • Cancer Research and Treatments
  • Cancer-related cognitive impairment studies
  • Advanced Radiotherapy Techniques
  • Radiopharmaceutical Chemistry and Applications
  • Renal cell carcinoma treatment
  • Healthcare professionals’ stress and burnout
  • Lymphoma Diagnosis and Treatment
  • Pancreatic and Hepatic Oncology Research
  • Cancer survivorship and care
  • CNS Lymphoma Diagnosis and Treatment

Loyola University Chicago
2009-2025

Edward Hines, Jr. VA Hospital
2016-2024

Loyola University Medical Center
2012-2022

Federal Medical Centre
2020

Loyola Medicine
2017

University of Illinois Chicago
2016

University of Iowa
2016

Living Streets
2005

4528 Background: Significant unmet need remains for people with cisplatin-ineligible (cis-ineligible) locally advanced or metastatic urothelial carcinoma (la/mUC). In the first-line (1L) setting, carboplatin-based regimens have demonstrated poor tolerability, modest objective response rate (ORR) and limited durability. PD-1/PD-L1 inhibitors demonstrate durable responses; however, only a minority of pts achieve (ORR 24-29%). Enfortumab vedotin (EV) is an antibody-drug conjugate (ADC)...

10.1200/jco.2021.39.15_suppl.4528 article EN Journal of Clinical Oncology 2021-05-20

ABSTRACT Purpose To explore the potential relationship between social media (SoMe) and burnout or overall wellbeing within field of oncology. Design A cross‐sectional study adult pediatric oncology professionals conducted using an anonymous electronic survey. The survey was disseminated through Children's Oncology Group (COG) SWOG Cancer Research Network (SWOG) member listservs. Results majority are not engaging on, with only 873/3000 (29%) SoMe professionally. Use associated statistically...

10.1002/pbc.31568 article EN cc-by-nc-nd Pediatric Blood & Cancer 2025-01-25

Inhibitory checkpoint blockade therapy is an immunomodulatory strategy that results in the restoration of T cell functions, and its efficacy depends on recognition tumor cells for destruction. Considering factors at play, one could propose anti-tumor responses will not occur if are immunologically invisible to cells. In this study, we tested a based modulation cancer cell's immunovisibility through HDAC inhibition. model (heterotopic orthotopic) mouse urothelial bladder cancer, demonstrated...

10.3389/fonc.2020.00699 article EN cc-by Frontiers in Oncology 2020-05-15

The current study was conducted to compare the overall survival (OS) of concurrent chemoradiotherapy (CCRT) versus radiotherapy (RT) alone in elderly patients (those aged ≥80 years) with muscle-invasive bladder cancer (MIBC).Patients years cT2-4, N0-3, M0 transitional cell MIBC who were treated curative RT (60-70 Gray) or CCRT identified National Cancer Data Base. Univariable and multivariable frailty analyses, as well 1-to-1 propensity score matching, used isolate association between OS.A...

10.1002/cncr.30719 article EN Cancer 2017-06-05

4564 Background: For patients (pts) with MIBC who are cisplatin-ineligible and undergoing radical cystectomy pelvic lymph node dissection (RC+PLND), no neoadjuvant treatment options have been shown to improve survival. Enfortumab vedotin (EV) is an antibody-drug conjugate directed Nectin-4, which highly expressed in urothelial cancer. EV, alone combination w/ pembrolizumab, has OS vs chemotherapy pts previously treated untreated locally advanced or metastatic cancer, respectively (Powles...

10.1200/jco.2024.42.16_suppl.4564 article EN Journal of Clinical Oncology 2024-06-01

Graduate medical and research training has drastically changed during the COVID-19 pandemic, with widespread implementation of virtual learning, redeployment from core rotations to care patients COVID-19, significant emotional physical stressors. The specific experience hematology-oncology (HO) fellows pandemic is not known.We conducted a mixed-methods study using survey Likert-style open-ended questions assess well-being HO fellows, including both clinical postdoctoral trainee members...

10.1200/op.21.00630 article EN cc-by-nc-nd JCO Oncology Practice 2022-01-06

The primary objective of this survey was to establish current practice in emergency departments the UK. Variation obtaining consent, how image collection is achieved, and images stored were considered be important outcomes. An initial postal questionnaire followed by phone posed questions about practical procedural issues when capturing clinical Altogether, 117 replied out 150 surveyed. Only 21 have a written policy permitting medico-legal case photography. A total 53 do take photographs...

10.1136/emj.2004.016972 article EN public-domain Emergency Medicine Journal 2005-10-21

Cancer care delivery is highly complex. Treatment involves coordination within oncology health-care teams and across other of referring primary specialty providers (a team teams). Each interfaces with patients caregivers to offer component parts comprehensive care. Because frequently obtain from divergent systems resulting in cross-system use, need mechanisms coordinate collaborate optimize clinical outcomes for all cancer patients. Transactive memory one potential strategy that can help...

10.1200/jop.2016.013730 article EN Journal of Oncology Practice 2016-08-31

The COVID-19 pandemic led to unprecedented challenges in medical training, and we sought assess the specific impact of on hematology-oncology (HO) fellowship programs.We conducted a cross-sectional anonymous online survey 103 HO program directors (PDs) conjunction with American Society Hematology (ASH) ASCO. We programs' clinical, educational, research activities, evaluate perceptions regarding PD trainee emotional mental health, identify ways support programs. Data were analyzed using...

10.1200/op.21.00634 article EN JCO Oncology Practice 2022-01-11

COVID-19 challenged medical practice and graduate education. Building on previous initiatives, we describe reflect the formative process goals of Hematology-Oncology Collaborative Videoconferencing Learning Initiative, a trainee-led multi-institutional virtual learning model.Clinical fellows faculty from 13 US training institutions developed consensus needs, goals, objectives, recruited presenters, generated multidisciplinary curriculum. Weekly Zoom conferences consisted two instructional...

10.1200/op.20.00960 article EN JCO Oncology Practice 2021-07-09

TPS5092 Background: Cisplatin-based chemotherapy is the standard for first-line (1L) patients (pts) with locally advanced/metastatic urothelial cancer (LA/mUC). PD-1/PD-L1 inhibitors have promising durability of responses but 1L use restricted to pts ineligible cisplatin-containing therapy and whose tumors express PD-L1 (CPS ≥10) or platinum-containing regardless status. Enfortumab vedotin (EV), an antibody-drug conjugate, delivers microtubule-disrupting agent monomethyl auristatin E cells...

10.1200/jco.2020.38.15_suppl.tps5092 article EN Journal of Clinical Oncology 2020-05-20

TPS203 Background: Two diverging paradigms have been studied in recent years to improve the survival of men with recurrent metastatic prostate cancer (PCa). First, multiple phase II randomized trials demonstrated improved long-term progression-free (PFS) metastasis-directed therapy (MDT) oligorecurrent PCa absence systemic therapy. Yet, most patients receiving MDT for develop progression new areas, arguing that is needed treat occult metastases. The second approach has recently whether...

10.1200/jco.2022.40.6_suppl.tps203 article EN Journal of Clinical Oncology 2022-02-16

The United States Veterans Affairs (VA) Health Care System has a strong history of conducting impactful oncology randomized clinical trials (RCTs). We developed phase II/III RCT to test the use metastasis-directed therapy in with oligometastatic prostate cancer (OMPC)—the first VA OMPC that leverages novel imaging and advanced radiotherapy techniques. To accomplish this, we trial network conduct study. In this manuscript, describe several challenges encountered study development/conduct our...

10.3390/curroncol31080358 article EN cc-by Current Oncology 2024-08-21

<b><i>Introduction:</i></b> Secondary cardiac malignancies are much more common than primary cancers. Metastatic cancers to the heart from other solid organs well known and carry a poor prognosis. <b><i>Case Presentation:</i></b> An 83-year-old Hispanic veteran presented with breathlessness, cough, weight loss. Imaging studies showed extensive pericardial effusion multiple pericardial/epicardial masses. Biopsy poorly differentiated metastatic...

10.1159/000506843 article EN Oncology Research and Treatment 2021-01-01

TPS5120 Background: The concept of metastasis-directed therapy (MDT) using radiation or surgery for oligometastatic (OM) prostate cancer (pCa) has evolved from an anecdotal hypothesis to a promising approach that may optimally balance toxicity and oncologic efficacy. Recently, there have been multiple smaller phase II randomized trials shown signal efficacy MDT in OM pCa. Most studies compared observation alone as the control arm, included only recurrent patients, up 3-5 sites metastasis. It...

10.1200/jco.2024.42.16_suppl.tps5120 article EN Journal of Clinical Oncology 2024-06-01

9022 Background: High quality education is crucial for hematology/oncology (H/O) training and lifelong learning. However, H/O has historically prioritized clinical research careers over medical careers. Consequently, few programs support educators. A CoP a group that shares “a concern or passion something they do learn how to it better as interact regularly.” We formed the ASCO Med Ed in 2021 provide collaborative network professional development venue Methods: Following published framework...

10.1200/jco.2024.42.16_suppl.9022 article EN Journal of Clinical Oncology 2024-06-01

11004 Background: Medical trainees are increasingly utilizing social media platforms for professional development, networking and education. Twitter chats (TC) a growing tool to engage health professionals in virtual multi-institutional, cross-discipline discussions. A meta-analysis of as residency education demonstrated high rates satisfaction concept retention. Despite rapid uptake, few studies address needs use implementation graduate medical Methods: We created account (@HOjournalclub)...

10.1200/jco.2020.38.15_suppl.11004 article EN Journal of Clinical Oncology 2020-05-20

14 Background: Approved treatments for metastatic melanoma (MM) and renal cell carcinoma (mRCC) include targeted agents, high dose interleukin-2 (HD IL-2) checkpoint inhibitors (CI). A subset of responders to HD-IL2 can achieve long term durable remissions (7-10%). Recently, data suggests that are possible with CI. Thus, despite increased toxicity, first-line immunotherapy is a reasonable consideration in carefully selected patients clear mRCC MM followed by CI upon relapse. Our study...

10.1200/jco.2019.37.8_suppl.14 article EN Journal of Clinical Oncology 2019-03-10

Background of the study: Physiotherapists in Nigeria renewed their practicing license annually through regulatory body and are provided with professional code ethics which stipulate appropriate conduct, behaviour to guild regulate practice profession however, level knowledge, attitude application ethical guidelines by Nigerian physiotherapists need be investigated. Aim Study: This study assessed perception relation practice. Methodology: The cross-sectional recruited 117 licenced working...

10.3329/bioethics.v10i1.48972 article EN cc-by-nc-nd Bangladesh Journal of Bioethics 2020-09-08

Expert knowledge is often shared among multidisciplinary academic teams at tumor boards (TBs) across the country, but these conversations exist in silos and do not reach wider oncology community.Using an oncologist-only question answer (Q&A) website, we sought to document expert insights from TBs National Cancer Institute-designated Comprehensive Centers (NCI-CCCs) provide educational benefits community.We designed a process with NCI-CCCs share discussions focused on areas of practice...

10.2196/33859 article EN cc-by JMIR Cancer 2022-05-19
Coming Soon ...